Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug

~ Promising Efficacy Against Difficult-to-treat Cancers, Including Triple Negative Breast Cancer, and Enhanced Effect of Standard-of-Care Chemotherapy During Preclinical Development ~ MUMBAI, India, July 20, 2023 /PRNewswire/ — Sathgen Therapeutics, a division of a leading chemicals…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.